Suppr超能文献

肝细胞胆管癌合并患者肝移植与肝切除术的比较:一项回顾性队列研究。

Liver transplantation versus resection for patients with combined hepatocellular cholangiocarcinoma: A retrospective cohort study.

作者信息

Mi Shizheng, Hou Ziqi, Qiu Guoteng, Jin Zhaoxing, Xie Qingyun, Huang Jiwei

机构信息

Department of Liver Surgery and Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu, China.

出版信息

Heliyon. 2023 Oct 13;9(10):e20945. doi: 10.1016/j.heliyon.2023.e20945. eCollection 2023 Oct.

Abstract

BACKGROUND

Combined hepatocellular cholangiocarcinoma (CHC) is a rare primary liver cancer, and whether liver transplantation should be implemented among CHC patients is still controversial. We intend to conduct a retrospective cohort study based on the Surveillance, Epidemiology, and End Results (SEER) database to investigate the prognosis of liver transplantation liver resection among CHC patients.

METHODS

Patients diagnosed with CHC (ICD-O-3:8180/3) and treated with transplantation or hepatectomy were extracted from the SEER database (2000-2018). We utilized Propensity Score Matching to control confounding bias. Kaplan-Meier curve was used for survival analysis, and Cox regression was used to find independent factors associated with prognosis.

RESULTS

We identified 123 (transplantation: 49; resection: 74) patients with CHC who were treated between 2004 and 2015. In the entire cohort, survival analysis demonstrated transplantation group was associated with better overall survival and cancer-specific survival (log-rank p = 0.004 and p = 0.003, respectively). In addition, liver transplantation still conferred better overall and cancer-specific survival than liver resection after Propensity Score Matching (log-rank p = 0.024 and p = 0.048, respectively). However, this advantage didn't appear in the subgroup, regardless of whether the tumor size was greater than 3 cm or not. (≤3 cm: OS log-rank p = 0.230, CSS log-rank p = 0.370; >3 cm: OS log-rank p = 0.110, CSS log-rank p = 0.084). Multivariate analysis validated the finding that liver transplantation was a protective factor for overall survival (HR = 0.55 [0.31-0.95], p = 0.032).

CONCLUSIONS

Liver transplantation may be an option in individuals with CHC and should be taken into consideration due to its advantages in terms of overall survival and cancer-specific survival. However, a sizable sample is required for future studies to determine which subset of CHC patients may benefit more from liver transplantation.

摘要

背景

肝内胆管癌合并肝细胞癌(CHC)是一种罕见的原发性肝癌,CHC患者是否应进行肝移植仍存在争议。我们打算基于监测、流行病学和最终结果(SEER)数据库进行一项回顾性队列研究,以调查CHC患者肝移植和肝切除术后的预后情况。

方法

从SEER数据库(2000 - 2018年)中提取诊断为CHC(ICD - O - 3:8180/3)并接受移植或肝切除术治疗的患者。我们采用倾向得分匹配法来控制混杂偏倚。采用Kaplan - Meier曲线进行生存分析,采用Cox回归分析来寻找与预后相关的独立因素。

结果

我们确定了123例在2004年至2015年间接受治疗的CHC患者(移植组:49例;切除组:74例)。在整个队列中,生存分析表明移植组的总生存期和癌症特异性生存期更好(对数秩检验p值分别为0.004和0.003)。此外,倾向得分匹配后,肝移植的总生存期和癌症特异性生存期仍优于肝切除(对数秩检验p值分别为0.024和0.048)。然而,无论肿瘤大小是否大于3 cm,该优势在亚组中均未出现。(≤3 cm:总生存期对数秩检验p值 = 0.230,癌症特异性生存期对数秩检验p值 = 0.370;>3 cm:总生存期对数秩检验p值 = 0.110,癌症特异性生存期对数秩检验p值 = 0.084)。多因素分析验证了肝移植是总生存期的保护因素这一发现(风险比 = 0.55 [0.31 - 0.95],p值 = 0.032)。

结论

肝移植可能是CHC患者的一种选择,鉴于其在总生存期和癌症特异性生存期方面的优势,应予以考虑。然而,未来研究需要大量样本以确定哪些CHC患者亚组可能从肝移植中获益更多。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6219/10590945/92fc7f640bab/gr1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验